About Xellia Pharmaceuticals
Xellia Pharmaceuticals is a Healthcare company based in Copenhagen (Denmark) founded in 1903, and was acquired by Novo Holdings in May 2013. Manufacturer of active pharmaceutical ingredients and finished dosage forms. The company has 52 employees. Its Indian entity Xellia Pharmaceuticals Private Limited reported revenue of βΉ28.32 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Founded in 1903 and headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals operates in the pharmaceutical sector with a focus on anti-infective therapies. Active pharmaceutical ingredients are supplied to companies worldwide, while finished dosage forms are provided mainly through contract manufacturing organizations. Research and development, manufacturing, and commercialization activities are conducted, with emphasis placed on sustainable practices for critical care treatments of serious infections.
- Headquarters Copenhagen, Denmark
- Employees 52
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website xellia.com
- Social LinkedIn X
- Acquired by Novo Holdings (May 2013)
- Legal Name Xellia Pharmaceuticals Private Limited
- Date of Incorporation 13 Sep, 2010
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹28.32 Cr
FY 2025 · +16% YoY
- Indian entity net profit₹2.28 Cr
FY 2025 · 8% margin
- Indian entity EBITDA₹3.71 Cr
FY 2025 · 13% margin
- Investors
- Employee Count52
- Acquired byNovo Holdings
(May 2013)
Associated legal entities of Xellia Pharmaceuticals
Xellia Pharmaceuticals operates through Xellia Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Xellia Pharmaceuticals Private Limited CIN U24230KA2010PTC055122 | Active | 13 Sep 2010 | Bangalore, Karnataka | ₹28.3 Cr | 52 | 4 | View details |
Investors in Xellia Pharmaceuticals
Xellia Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark |
Investor details for Xellia Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Xellia Pharmaceuticals Private Limited (Xellia Pharmaceuticals)
Xellia Pharmaceuticals Private Limited is the primary company behind Xellia Pharmaceuticals. The board of Xellia Pharmaceuticals Private Limited currently have 4 directors; the longest-serving is Soren Hostrup, appointed in 2024. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Soren Hostrup DIN 10724148 | Director | 20 Aug 2024 | 2 yrs 2 mo | Xellia Pharmaceuticals Private Limited |
| Kasi Visweswara Venkata Satya Lakshmi Nagakishore Sripada DIN 11416360 | Additional Director | 16 Dec 2025 | 11 mo | Xellia Pharmaceuticals Private Limited |
| Eva Blem DIN 11469480 | Additional Director | 12 Jan 2026 | 10 mo | Xellia Pharmaceuticals Private Limited |
| Per Bork Eppers DIN 11469479 | Additional Director | 12 Jan 2026 | 10 mo | Xellia Pharmaceuticals Private Limited |
People of Xellia Pharmaceuticals
92 people are tracked at Xellia Pharmaceuticals (37 in leadership, 5 in board & advisors, 50 in team); the tracked headcount is 52.
| Name | Role | Group |
|---|---|---|
Anders Dorph | Senior Director, Global Supply Chain | Leadership |
Rahul Chhawsaria | Associate Director Global Supply Chain | Leadership |
Aurélien Grosso | Senior Director Global Supply Chain | Leadership |
Josef Christensen | Director, Strategy & Commercial Transformation | Leadership |
Ken Ruggiero | Head Of Facilities Management | Leadership |
Vicente Oller Más | CFO | Leadership |
Norbert Denes | Head Of Finance Hungary & Croatia | Leadership |
Vidya Viswanathan | Director, India Finance, Admin & HR And Global Fp&a | Leadership |
Jeppe Palm Beckmann | Director - Head Of Transformation, Global Product Supply & Quality | Leadership |
Anne Mette Nygard | Director Strategic Programs | Leadership |
| Site Director India | Leadership | |
Florian Falch | Chief People & Culture Officer | Leadership |
Michael Kocher | CEO | Leadership |
Alexander Sproedt | Chief Strategy & Transformation Officer | Leadership |
Gael Bernard | Chief Commercial Officer - Executive Vice President | Leadership |
Dan Gnolfo | Vice President Of Finance, North America | Leadership |
Eva Farkas | Managing Director (quality) | Leadership |
Peter Baker | Chief Commercial Officer | Leadership |
Doug Knutson | Director, Commercial Finance & Sales Effectiveness | Leadership |
Søren Hostrup | Chief Legal Officer - Executive Vice President | Leadership |
72 more people are available in the full profile.
Complete people profiles for Xellia Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Xellia Pharmaceuticals
Figures of Xellia Pharmaceuticals Private Limited, the primary company behind Xellia Pharmaceuticals, for FY 2025. Revenue was ₹28.32 Cr (+16% year on year). Net profit was ₹2.28 Cr (8% margin). EBITDA was ₹3.71 Cr (13% margin). Revenue has grown at a compounded annual rate of +16% over three years and +12% over five years.
- ₹28.32 CrRevenue · FY 2025 · +16% YoY
- ₹2.28 CrNet profit · 8% margin
- ₹3.71 CrEBITDA · 13% margin
- ₹1 LakhPaid-up capital
- 52Employees (provident fund records)
- +16%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Xellia Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Xellia Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Xellia Pharmaceuticals
2 dated milestones of Xellia Pharmaceuticals across 110 years, from founding to its latest funding, stage changes and deals.
- Founded Xellia Pharmaceuticals is founded.
- Exit Acquired by Novo Holdings.
Web traffic of Xellia Pharmaceuticals
The website of Xellia Pharmaceuticals (xellia.com) receives about 6.5K visits a month and ranks #3,179,039 among all websites worldwide, #4,186 in Biotechnology and Pharmaceuticals.
- Monthly visits6.5K
- Unique visitors2.7K
per month
- Global rank#3,179,039
among all websites
- Category rank#4,186
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.6
- Average visit25 sec
- DevicesDesktop 26% Β· Mobile 74%
Websites whose visitors overlap most with Xellia Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lundbeck.com | 100% | 137.6K | #280,857 | View details | |
| contractpharma.com | 100% | 67.7K | #631,663 | View details | |
empr.com | empr.com | 60% | #153,602 | β | |
mims.com | mims.com | 60% | #27,323 | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xellia Pharmaceuticals
Xellia Pharmaceuticals was founded in 1903.
Xellia Pharmaceuticals is headquartered in Copenhagen, Denmark.
Xellia Pharmaceuticals has 52 employees.
The primary company behind Xellia Pharmaceuticals, Xellia Pharmaceuticals Private Limited, reported revenue of βΉ28.32 Cr for FY 2025, up 16% year on year.
Founded in 1903 and headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals operates in the pharmaceutical sector with a focus on anti-infective therapies. Active pharmaceutical ingredients are supplied to companies worldwide, while finished dosage forms are provided mainly through contract manufacturing organizations. Research and development, manufacturing, and commercialization activities are conducted, with emphasis placed on sustainable practices for critical care treatments of serious infections.
Xellia Pharmaceuticals has 1 investor. Key investors include Novo Holdings.
Xellia Pharmaceuticals operates through Xellia Pharmaceuticals Private Limited.
Yes. Xellia Pharmaceuticals was acquired by Novo Holdings in May 2013.
The legal entities of Xellia Pharmaceuticals currently have 4 directors, including Soren Hostrup, Eva Blem, Per Bork Eppers and others.
